Madrigal Pharmaceuticals (MDGL) Capital Expenditures (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Capital Expenditures of $4.3 million for Q2 2026, up 10.5% quarter-over-quarter from $3.8 million in Q1 2026.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) Capital Expenditures (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Capital Expenditures for 17 consecutive years, with $4.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Capital Expenditures changed N/A year-over-year to $4.3 million; the TTM figure through Jun 2026 stood at $8.6 million (up 779.77% YoY), while the FY2025 annual figure was $467000.0, down 68.06% from the prior year.
- Capital Expenditures grew to $4.3 million in Q2 2026 per MDGL's latest filing, from $3.8 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.3 million in Q2 2026 and bottomed at -$390000.0 in Q4 2025.
- Historically, Capital Expenditures has averaged $732937.5 across 5 years, with a median of $163000.0 in 2024.
- Annual changes were most pronounced in 2022 — Capital Expenditures jumped 5050.0% — and 2025, when it plunged 300.0%.
- Madrigal Pharmaceuticals' Capital Expenditures stood at $29000.0 in 2022, then soared by 3472.41% to $1.0 million in 2023, then sank by 81.18% to $195000.0 in 2024, then slumped by 300.0% to -$390000.0 in 2025, then soared by 1190.51% to $4.3 million in 2026.
- Business Quant data shows MDGL's Capital Expenditures at $4.3 million in Q2 2026, $3.8 million in Q1 2026, and -$390000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Madrigal Pharmaceuticals | 15.79 Bn | 14.96 Bn | - | 4.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.25 Mn |
| Mar 31, 2026 | 3.85 Mn |
| Dec 31, 2025 | -390,000.00 |
| Sep 30, 2025 | 857,000.00 |
| Dec 31, 2024 | 195,000.00 |
| Sep 30, 2024 | 779,000.00 |
| Jun 30, 2024 | 131,000.00 |
| Mar 31, 2024 | 357,000.00 |
| Dec 31, 2023 | 1.04 Mn |
| Sep 30, 2023 | 339,000.00 |
| Jun 30, 2023 | 69,000.00 |
| Mar 31, 2023 | 35,000.00 |
| Dec 31, 2022 | 29,000.00 |
| Sep 30, 2022 | 33,000.00 |
| Jun 30, 2022 | 103,000.00 |
| Mar 31, 2022 | 52,000.00 |
| Dec 31, 2021 | 113,000.00 |
| Sep 30, 2021 | 50,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Mar 31, 2021 | 44,000.00 |